サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1508457

再生不良性貧血市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Aplastic Anemia Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 140 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
再生不良性貧血市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年05月02日
発行: Transparency Market Research
ページ情報: 英文 140 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

再生不良性貧血市場- 調査範囲

TMRの調査レポート「再生不良性貧血の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の再生不良性貧血市場の収益と予測を提供しています。また、2024年から2034年までの世界の再生不良性貧血市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、再生不良性貧血市場を推察しました。

市場スナップショット
2023年の市場規模 67億米ドル
2034年の市場規模 108億米ドル
CAGR 4.3%

当レポートでは、世界の再生不良性貧血市場の競合情勢について調査しています。世界の再生不良性貧血市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の再生不良性貧血市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界市場分析と予測, 2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19による産業への影響

第6章 世界市場分析と予測：疾患別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：疾患別, 2020-2034年
    • 後天性
    • 遺伝性
  • 市場の魅力：疾患別

第7章 世界市場分析と予測：治療タイプ別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：治療タイプ別, 2020-2034年
    • 骨髄輸血・幹細胞療法
    • 輸血
    • 薬剤療法
  • 市場の魅力：治療タイプ別

第8章 世界市場分析と予測：投与方法別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：投与方法別, 2020-2034年
    • 注射
    • 経口
    • その他
  • 市場の魅力：投与方法別

第9章 世界市場分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果・発展
  • 市場金額予測：エンドユーザー別, 2020-2034年
    • 病院
    • 専門クリニック
    • その他
  • 市場の魅力：エンドユーザー別

第10章 世界市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別, 2020-2034年
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力：地域別

第11章 北米の市場分析と予測

第12章 欧州の市場分析と予測

第13章 アジア太平洋地域の市場分析と予測

第14章 ラテンアメリカの市場分析と予測

第15章 中東・アフリカの市場分析と予測

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層と規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • Eisai Co., Ltd.
    • Pfizer Inc.
    • Sanofi S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Allergan plc
    • Merz Pharma GmbH & Co. KGaA
    • Johnson & Johnson Services Inc.
    • F. Hoffmann-La Roche AG
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • Bayer AG
    • その他
図表

List of Tables

  • Table 01: Global Aplastic Anemia Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 02: Global Aplastic Anemia Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 03: Global Aplastic Anemia Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 04: Global Aplastic Anemia Market Size (US$ Bn) Forecast, by Mode of Administration, 2020-2034
  • Table 05: Global Aplastic Anemia Market Size (US$ Bn) Forecast, by Region, 2020-2034
  • Table 06: North America Aplastic Anemia Market Size (US$ Bn) Forecast, by Country, 2020-2034
  • Table 07: North America Aplastic Anemia Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 08: North America Aplastic Anemia Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 09: North America Aplastic Anemia Market Size (US$ Bn) Forecast, by Mode of Administration, 2020-2034
  • Table 10: North America Aplastic Anemia Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 11: Europe Aplastic Anemia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Aplastic Anemia Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 13: Europe Aplastic Anemia Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 14: Europe Aplastic Anemia Market Size (US$ Bn) Forecast, by Mode of Administration, 2020-2034
  • Table 15: Europe Aplastic Anemia Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 16: Asia Pacific Aplastic Anemia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Aplastic Anemia Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 18: Asia Pacific Aplastic Anemia Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 19: Asia Pacific Aplastic Anemia Market Size (US$ Bn) Forecast, by Mode of Administration, 2020-2034
  • Table 20: Asia Pacific Aplastic Anemia Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 21: Latin America Aplastic Anemia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Aplastic Anemia Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 23: Latin America Aplastic Anemia Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 24: Latin America Aplastic Anemia Market Size (US$ Bn) Forecast, by Mode of Administration, 2020-2034
  • Table 25: Latin America Aplastic Anemia Market Size (US$ Bn) Forecast, by End-user, 2020-2034
  • Table 26: Middle East & Africa Aplastic Anemia Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Aplastic Anemia Market Size (US$ Bn) Forecast, by Disease Type, 2020-2034
  • Table 28: Middle East & Africa Aplastic Anemia Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034
  • Table 29: Middle East & Africa Aplastic Anemia Market Size (US$ Bn) Forecast, by Mode of Administration, 2020-2034
  • Table 30: Middle East & Africa Aplastic Anemia Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Aplastic Anemia Market Size (US$ Bn), by Region, 2023 and 2034
  • Figure 02: Global Aplastic Anemia Market Revenue (US$ Bn), by Disease Type, 2023
  • Figure 03: Global Aplastic Anemia Market Value Share, by Disease Type, 2023
  • Figure 04: Global Aplastic Anemia Market Revenue (US$ Bn), by Treatment Type, 2023
  • Figure 05: Global Aplastic Anemia Market Value Share, by Treatment Type, 2023
  • Figure 06: Global Aplastic Anemia Market Revenue (US$ Bn), by Mode of Administration, 2023
  • Figure 07: Global Aplastic Anemia Market Value Share, by Mode of Administration, 2023
  • Figure 08: Global Aplastic Anemia Market Revenue (US$ Bn), by End-user, 2023
  • Figure 09: Global Aplastic Anemia Market Value Share, by End-user, 2023
  • Figure 10: Global Aplastic Anemia Market Value Share, by Region, 2023
  • Figure 11: Global Aplastic Anemia Market Value (US$ Bn) Forecast, 2020-2034
  • Figure 12: Global Aplastic Anemia Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 13: Global Aplastic Anemia Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 14: Global Aplastic Anemia Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 15: Global Aplastic Anemia Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 16: Global Aplastic Anemia Market Value Share Analysis, by Mode of Administration, 2023 and 2034
  • Figure 17: Global Aplastic Anemia Market Attractiveness Analysis, by Mode of Administration, 2024-2034
  • Figure 18: Global Aplastic Anemia Market Revenue (US$ Bn), by End-user, 2023
  • Figure 19: Global Aplastic Anemia Market Value Share, by End-user, 2023
  • Figure 20: Global Aplastic Anemia Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Aplastic Anemia Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Aplastic Anemia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Aplastic Anemia Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Aplastic Anemia Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Aplastic Anemia Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 26: North America Aplastic Anemia Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 27: North America Aplastic Anemia Market Value Share Analysis, by Mode of Administration, 2023 and 2034
  • Figure 28: North America Aplastic Anemia Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 29: North America Aplastic Anemia Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 30: North America Aplastic Anemia Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 31: North America Aplastic Anemia Market Attractiveness Analysis, by Mode of Administration, 2024-2034
  • Figure 32: North America Aplastic Anemia Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 33: Europe Aplastic Anemia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Aplastic Anemia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Aplastic Anemia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Aplastic Anemia Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 37: Europe Aplastic Anemia Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 38: Europe Aplastic Anemia Market Value Share Analysis, by Mode of Administration, 2023 and 2034
  • Figure 39: Europe Aplastic Anemia Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Europe Aplastic Anemia Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 41: Europe Aplastic Anemia Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 42: Europe Aplastic Anemia Market Attractiveness Analysis, by Mode of Administration, 2024-2034
  • Figure 43: Europe Aplastic Anemia Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 44: Asia Pacific Aplastic Anemia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Aplastic Anemia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Aplastic Anemia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Aplastic Anemia Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 48: Asia Pacific Aplastic Anemia Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 49: Asia Pacific Aplastic Anemia Market Value Share Analysis, by Mode of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Aplastic Anemia Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 51: Asia Pacific Aplastic Anemia Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 52: Asia Pacific Aplastic Anemia Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 53: Asia Pacific Aplastic Anemia Market Attractiveness Analysis, by Mode of Administration, 2024-2034
  • Figure 54: Asia Pacific Aplastic Anemia Market Attractiveness Analysis, by End-user, 2023-2034
  • Figure 55: Latin America Aplastic Anemia Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Aplastic Anemia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Aplastic Anemia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Aplastic Anemia Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 59: Latin America Aplastic Anemia Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 60: Latin America Aplastic Anemia Market Value Share Analysis, by Mode of Administration, 2023 and 2034
  • Figure 61: Latin America Aplastic Anemia Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 62: Latin America Aplastic Anemia Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 63: Latin America Aplastic Anemia Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 64: Latin America Aplastic Anemia Market Attractiveness Analysis, by Mode of Administration, 2024-2034
  • Figure 65: Latin America Aplastic Anemia Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 66: Middle East & Africa Aplastic Anemia Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Aplastic Anemia Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Aplastic Anemia Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Aplastic Anemia Market Value Share Analysis, by Disease Type, 2023 and 2034
  • Figure 70: Middle East & Africa Aplastic Anemia Market Value Share Analysis, by Treatment Type, 2023 and 2034
  • Figure 71: Middle East & Africa Aplastic Anemia Market Value Share Analysis, by Mode of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Aplastic Anemia Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 73: Middle East & Africa Aplastic Anemia Market Attractiveness Analysis, by Disease Type, 2024-2034
  • Figure 74: Middle East & Africa Aplastic Anemia Market Attractiveness Analysis, by Treatment Type, 2024-2034
  • Figure 75: Middle East & Africa Aplastic Anemia Market Attractiveness Analysis, by Mode of Administration, 2024-2034
  • Figure 76: Middle East & Africa Aplastic Anemia Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL86040

Aplastic Anemia Market - Scope of Report

TMR's report on the global aplastic anemia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global aplastic anemia market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global aplastic anemia market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the aplastic anemia market.

Market Snapshot
Market Value in 2023US$ 6.7 Bn
Market Value in 2034US$ 10.8 Bn
CAGR4.3%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global aplastic anemia market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global aplastic anemia market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global aplastic anemia market.

The report delves into the competitive landscape of the global aplastic anemia market. Key players operating in the global aplastic anemia market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global aplastic anemia market profiled in this report.

Key Questions Answered in Global aplastic anemia Market Report:

  • What is the sales/revenue generated by aplastic anemia across all regions during the forecast period?
  • What are the opportunities in the global aplastic anemia market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Aplastic Anemia Market - Research Objectives and Research Approach

The comprehensive report on the global aplastic anemia market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global aplastic anemia market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global aplastic anemia market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Aplastic Anemia Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Aplastic Anemia Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Aplastic Anemia Market Analysis and Forecast, by Disease Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Disease Type, 2020-2034
    • 6.3.1. Acquired Aplastic Anemia
    • 6.3.2. Inherited Aplastic Anemia
  • 6.4. Market Attractiveness, by Disease Type

7. Global Aplastic Anemia Market Analysis and Forecast, by Treatment Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 7.3.1. Bone Marrow Transfusion/Stem Cell Therapy
    • 7.3.2. Blood Transfusion
    • 7.3.3. Drug Therapy
  • 7.4. Market Attractiveness, by Treatment Type

8. Global Aplastic Anemia Market Analysis and Forecast, by Mode of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Mode of Administration, 2020-2034
    • 8.3.1. Injectable
    • 8.3.2. Oral
    • 8.3.3. Others
  • 8.4. Market Attractiveness, by Mode of Administration

9. Global Aplastic Anemia Market Analysis and Forecast, by End-user

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by End-user, 2020-2034
    • 9.3.1. Hospitals
    • 9.3.2. Specialty Clinics
    • 9.3.3. Others
  • 9.4. Market Attractiveness, by End-user

10. Global Aplastic Anemia Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Aplastic Anemia Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Disease Type, 2020-2034
    • 11.2.1. Acquired Aplastic Anemia
    • 11.2.2. Inherited Aplastic Anemia
  • 11.3. Market Attractiveness, by Disease Type
  • 11.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.4.1. Bone Marrow Transfusion/Stem Cell Therapy
    • 11.4.2. Blood Transfusion
    • 11.4.3. Drug Therapy
  • 11.5. Market Attractiveness, by Treatment Type
  • 11.6. Market Value Forecast, by Mode of Administration, 2020-2034
    • 11.6.1. Injectable
    • 11.6.2. Oral
    • 11.6.3. Others
  • 11.7. Market Attractiveness, by Mode of Administration
  • 11.8. Market Value Forecast, by End-user, 2020-2034
    • 11.8.1. Hospitals
    • 11.8.2. Specialty Clinics
    • 11.8.3. Others
    • 11.8.4. Market Attractiveness, by End-user
  • 11.9. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.9.1. U.S.
    • 11.9.2. Canada
  • 11.10. Market Attractiveness Analysis
    • 11.10.1. By Disease Type
    • 11.10.2. By Treatment Type
    • 11.10.3. By Mode of Administration
    • 11.10.4. By End-user
    • 11.10.5. By Country

12. Europe Aplastic Anemia Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Disease Type, 2020-2034
    • 12.2.1. Acquired Aplastic Anemia
    • 12.2.2. Inherited Aplastic Anemia
  • 12.3. Market Attractiveness, by Disease Type
  • 12.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.4.1. Bone Marrow Transfusion/Stem Cell Therapy
    • 12.4.2. Blood Transfusion
    • 12.4.3. Drug Therapy
  • 12.5. Market Attractiveness, by Treatment Type
  • 12.6. Market Value Forecast, by Mode of Administration, 2020-2034
    • 12.6.1. Injectable
    • 12.6.2. Oral
    • 12.6.3. Others
    • 12.6.4. Market Attractiveness, by Mode of Administration
  • 12.7. Market Value Forecast, by End-user, 2020-2034
    • 12.7.1. Hospitals
    • 12.7.2. Specialty Clinics
    • 12.7.3. Others
  • 12.8. Market Attractiveness, by End-user
  • 12.9. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.9.1. Germany
    • 12.9.2. U.K.
    • 12.9.3. France
    • 12.9.4. Italy
    • 12.9.5. Spain
    • 12.9.6. Rest of Europe
  • 12.10. Market Attractiveness Analysis
    • 12.10.1. By Disease Type
    • 12.10.2. By Treatment Type
    • 12.10.3. By Mode of Administration
    • 12.10.4. By End-user
    • 12.10.5. By Country/Sub-region

13. Asia Pacific Aplastic Anemia Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Disease Type, 2020-2034
    • 13.2.1. Acquired Aplastic Anemia
    • 13.2.2. Inherited Aplastic Anemia
  • 13.3. Market Attractiveness, by Disease Type
  • 13.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.4.1. Bone Marrow Transfusion/Stem Cell Therapy
    • 13.4.2. Blood Transfusion
    • 13.4.3. Drug Therapy
  • 13.5. Market Attractiveness, by Treatment Type
  • 13.6. Market Value Forecast, by Mode of Administration, 2020-2034
    • 13.6.1. Injectable
    • 13.6.2. Oral
    • 13.6.3. Others
  • 13.7. Market Attractiveness, by Mode of Administration
  • 13.8. Market Value Forecast, by End-user, 2020-2034
    • 13.8.1. Hospitals
    • 13.8.2. Specialty Clinics
    • 13.8.3. Others
    • 13.8.4. Market Attractiveness, by End-user
  • 13.9. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.9.1. China
    • 13.9.2. Japan
    • 13.9.3. India
    • 13.9.4. Australia & New Zealand
    • 13.9.5. Rest of Asia Pacific
  • 13.10. Market Attractiveness Analysis
    • 13.10.1. By Disease Type
    • 13.10.2. By Treatment Type
    • 13.10.3. By Mode of Administration
    • 13.10.4. By End-user
    • 13.10.5. By Country/Sub-region

14. Latin America Aplastic Anemia Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Disease Type, 2020-2034
    • 14.2.1. Acquired Aplastic Anemia
    • 14.2.2. Inherited Aplastic Anemia
  • 14.3. Market Attractiveness, by Disease Type
  • 14.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.4.1. Bone Marrow Transfusion/Stem Cell Therapy
    • 14.4.2. Blood Transfusion
    • 14.4.3. Drug Therapy
  • 14.5. Market Attractiveness, by Treatment Type
  • 14.6. Market Value Forecast, by Mode of Administration, 2020-2034
    • 14.6.1. Injectable
    • 14.6.2. Oral
    • 14.6.3. Others
  • 14.7. Market Attractiveness, by Mode of Administration
  • 14.8. Market Value Forecast, by End-user, 2020-2034
    • 14.8.1. Hospitals
    • 14.8.2. Specialty Clinics
    • 14.8.3. Others
    • 14.8.4. Market Attractiveness, by End-user
  • 14.9. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.9.1. Brazil
    • 14.9.2. Mexico
    • 14.9.3. Rest of Latin America
  • 14.10. Market Attractiveness Analysis
    • 14.10.1. By Disease Type
    • 14.10.2. By Treatment Type
    • 14.10.3. By Mode of Administration
    • 14.10.4. By End-user
    • 14.10.5. By Country/Sub-region

15. Middle East & Africa Aplastic Anemia Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Disease Type, 2020-2034
    • 15.2.1. Acquired Aplastic Anemia
    • 15.2.2. Inherited Aplastic Anemia
  • 15.3. Market Attractiveness, by Disease Type
  • 15.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 15.4.1. Bone Marrow Transfusion/Stem Cell Therapy
    • 15.4.2. Blood Transfusion
    • 15.4.3. Drug Therapy
  • 15.5. Market Attractiveness, by Treatment Type
  • 15.6. Market Value Forecast, by Mode of Administration, 2020-2034
    • 15.6.1. Injectable
    • 15.6.2. Oral
    • 15.6.3. Others
    • 15.6.4. Market Attractiveness, by Mode of Administration
  • 15.7. Market Value Forecast, by End-user, 2020-2034
    • 15.7.1. Hospitals
    • 15.7.2. Specialty Clinics
    • 15.7.3. Others
  • 15.8. Market Attractiveness, by End-user
  • 15.9. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.9.1. GCC Countries
    • 15.9.2. South Africa
    • 15.9.3. Rest of Middle East & Africa
  • 15.10. Market Attractiveness Analysis
    • 15.10.1. By Disease Type
    • 15.10.2. By Treatment Type
    • 15.10.3. By Mode of Administration
    • 15.10.4. By End-user
    • 15.10.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Eisai Co., Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Pfizer Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Sanofi S.A.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Teva Pharmaceutical Industries Ltd.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Novartis AG
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Allergan plc
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Merz Pharma GmbH & Co. KGaA
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Johnson & Johnson Services Inc.
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. F. Hoffmann-La Roche AG
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. AbbVie Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Takeda Pharmaceutical Company Limited
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Bayer AG
      • 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.12.2. Product Portfolio
      • 16.3.12.3. Financial Overview
      • 16.3.12.4. SWOT Analysis
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Others
      • 16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.13.2. Product Portfolio
      • 16.3.13.3. Financial Overview
      • 16.3.13.4. SWOT Analysis
      • 16.3.13.5. Strategic Overview